following a full submission
sunitinib (Sutent®) is accepted for use within NHS Scotland.
Indication under review: Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults.
Treatment with sunitinib improved progression free survival compared with placebo in patients with well-differentiated neuroendocrine carcinoma of the pancreas who were receiving best supportive care, including somatostatin analogues if required for symptomatic control.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of sunitinib. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland.
Download detailed advice128KB (PDF)
Medicine details
- Medicine name:
- sunitinib (Sutent)
- SMC ID:
- 698/11
- Indication:
- Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 09 May 2011